PT-141 (Bremelanotide)
PEPTIDES+ MEMBERS ONLY
INDICATIONS FOR USE
FDA-approved for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Off-label, PT-141 has been used in both men and women to address sexual dysfunction, including erectile dysfunction (ED) and low libido.
ROUTE OF ADMINISTRATION
Subcutaneous injection, typically administered into the abdomen or thigh.
FORMULATIONS AND PRICING
| Formulations | Price |
|---|---|
| 50mg nasal spray (10mg/mL x 5mL) | $125 |
| 20mg vial (10mg/mL x 2mL) | $105 |
COMMON INITIAL DOSING REGIMENS
The recommended FDA-approved dose for HSDD is 1.75 mg administered subcutaneously as needed, approximately 45 minutes before anticipated sexual activity. Doses may be adjusted off-label for individual responses in treating ED or low libido.
MECHANISM OF ACTION
PT-141 (Bremelanotide) is a melanocortin receptor agonist, primarily targeting the melanocortin 4 receptor (MC4R) in the central nervous system. Unlike phosphodiesterase type 5 inhibitors (e.g., sildenafil), PT-141 works centrally to modulate sexual desire and arousal rather than focusing solely on vascular changes. Activation of MC4R enhances dopaminergic signaling pathways associated with sexual desire, leading to increased libido and responsiveness to sexual stimuli.
In men, PT-141 may indirectly improve erectile function through central arousal pathways, while in women, it enhances sexual interest and receptivity.
COMMON SIDE EFFECTS
Gastrointestinal: Nausea is the most frequently reported side effect, occurring in up to 40% of users. Vomiting and abdominal discomfort may also occur.
Cardiovascular: Transient increases in blood pressure and decreases in heart rate have been reported. These effects are typically mild but necessitate caution in patients with pre-existing cardiovascular conditions.
Neurological: Headache and flushing are common, especially with higher doses. Fatigue or dizziness may occur less frequently.
Injection Site: Localized reactions, such as erythema, swelling, or tenderness, may occur at the site of administration.
Rare but Severe: Severe hypertension has been reported, particularly in patients with predisposing conditions or when combined with other medications affecting blood pressure.
CONTRAINDICATIONS
Absolute: Uncontrolled hypertension or known hypersensitivity to bremelanotide or its excipients.
Relative: Patients with a history of cardiovascular disease, cerebrovascular events, or high cardiovascular risk should use PT-141 with caution. The transient blood pressure effects may exacerbate underlying conditions.
ADDITIONAL NOTES ON EFFICACY
PT-141 is unique in its mechanism of action, targeting the brain’s arousal centers rather than focusing solely on peripheral vasodilation. This distinction makes it particularly useful for individuals with low libido or HSDD who do not respond to traditional treatments like PDE5 inhibitors. PT-141 is not recommended for daily use and should be reserved for on-demand therapy, as frequent administration may increase the likelihood of side effects.
MORE INFORMATION
FDA Safety Data Sheet may be found here.